最新ニュース Alvotech (NASDAQ:ALVO) 株価情報

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

B of A Securities analyst Kalei Akamine downgrades ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Buy to Neutral and lowers the price target from $138 to $107.

News

Downgrades

Price Target

Analyst Ratings

B of A Securities Downgrades ConocoPhillips to Neutral, Lowers Price Target to $107

WIIM

IFRX

InflaRx shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $10.

B of A Securities analyst Kalei Akamine upgrades Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) from Neutral to Buy and lowers the price target from $202 to $170.

Upgrades

FANG

B of A Securities Upgrades Diamondback Energy to Buy, Lowers Price Target to $170

CIBC analyst Hamir Patel maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and lowers the price target from $55 to $47.

MEOH

CIBC Maintains Outperformer on Methanex, Lowers Price Target to $47

B of A Securities analyst Noah Hungness upgrades Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) from Neutral to Buy and lowers the price target from $125 to $114.

CHRD

B of A Securities Upgrades Chord Energy to Buy, Lowers Price Target to $114

UAVS

AgEagle Aerial Systems shares are trading lower after the company announced it received a NYSE non-compliance notice regarding its minimums stockholders equity.

B of A Securities analyst Nat Schindler upgrades Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Underperform to Neutral and maintains the price target from $53 to $53.

UPST

B of A Securities Upgrades Upstart Hldgs to Neutral, Maintains Price Target to $53

TZOO

Travelzoo shares are trading higher following a Q1 revenue beat. Additionally, the company issued Q2 revenue guidance above estimates.

Argus Research analyst John Staszak reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Hold and maintains $490 price target.

Reiteration

Argus Research Reiterates Hold on Domino's Pizza, Maintains $490 Price Target

SAIH

Saiheat shares are trading higher after the company reported a year-over-year increase in FY24 EPS results.

WLDS

Wearable Devices shares are trading higher after the company announced it raised $1.2 million in gross proceeds through a warrant inducement agreement.

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Outperform and raises the price target from $279 to $282.

Keefe, Bruyette & Woods Maintains Outperform on RenaissanceRe Holdings, Raises Price Target to $282

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.44% on an annualized basis producing an average annual return of 21.65%. Currently, Meta Platforms has a market capitalization of $1.39 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $6,983.12 today based on a price of $550.34 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745941512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Market Perform and lowers the price target from $88 to $86.

Keefe, Bruyette & Woods Maintains Market Perform on Principal Financial Group, Lowers Price Target to $86

FISI

Financial Institutions shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Over the past three weeks, shares of Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) have declined by 8%, <a href="https://www.benzinga.com/topic/s-p-500">underperforming the S&amp;P 500</a> by more than 1,000 basis points, according to BofA Securities.
The Progressive Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8bb85e9300015f1ad8/joshua-shanker">Analyst Joshua Shanker</a> upgraded the rating from Neutral to Buy, while raising the price target from $297 to $312.
The Progressive Thesis: Earlier this month, the company announced its March 2025 results, adding a net 572,000 new personal auto customers, representing a month of the highest growth in its history, Shankar said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"It remains to be seen to what degree tariffs will be implemented by the Trump administration, creating uncertainty," the analyst wrote.
Shankar pointed out that supply-chain disruptions during the pandemic and post-pandemic periods resulted in the steepest auto insurance price hikes in 50 years, boosting profitability and market share gains for Progressive. Similarly tariff-induced inflation may act as "a tailwind to Progressive&#8217;s success and PGR stock performance," he further stated.
PGR Price Action: Shares of Progressive had risen by 1.7% to $274.19 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Dividend Investor Making $6,000/Month Shares Portfolio; Bought More on Recent &#8216;Bloody Day&#8217; Selloff — &#8216;Keep Grinding Until We Don&#8217;t Have To&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Movers

Progressive's Pain May Turn To Gain As Tariff Inflation Creates A Surprising Tailwind

Universal Logistics shares are trading lower after Stifel cut its price target on the stock from $37 to $29.

TD Cowen analyst Derick Ma initiates coverage on Faraday Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FDY#TSX">FDY</a>) with a Buy rating and announces Price Target of C$1.25.

Initiation

TSX:FDY

TD Cowen Initiates Coverage On Faraday Copper with Buy Rating, Announces Price Target of C$1.25

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) with a Market Perform and raises the price target from $21 to $23.

Keefe, Bruyette & Woods Maintains Market Perform on PCB Bancorp, Raises Price Target to $23

Scotiabank analyst Brandon Bingham maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Sector Outperform and lowers the price target from $201 to $199.

TRGP

Scotiabank Maintains Sector Outperform on Targa Resources, Lowers Price Target to $199

Health Care

Legal

Press Releases

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

General

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Comments

Alvotech

ニュース

最新ニュース Alvotech (NASDAQ:ALVO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル